MARKET WIREYahoo Finance Singapore • 15h ago
Palisade Bio, Inc. (PALI) stock price, news, quote and historyYahoo Finance Singapore report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
Why PALI Stock dropped -2.52% Today — RQD Quant Desk Flash
$1.16 -2.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.15
Palisade Bio Inc. (PALI) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $202.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PALI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PALI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Palisade Bio Inc. (NASDAQ: PALI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.16 (-2.52% 1D, market cap $202.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PALI compare to ARTV and PLX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PALI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARTV (Artiva Biotherapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $204.8M) and PLX (Protalix BioTherapeutics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -13.0%, cap $208.7M). Among the 5-stock peer group, PALI leads on earnings multiple (N/A) while PLX leads on capital efficiency (-13.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PALI?
▼
Per PALI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001357459), Palisade Bio Inc. generated $0 in revenue, -$16.8M in net income, and -$10.8M in free cash flow against $134.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.15 (-0.64%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PALI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY PALI SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.59-15.7% Next Q
40
Q2 (-2Q)Grade E$1.34-8.2% Next Q
37
Q3 (-1Q)Grade E$1.23-5.7% Next Q
35
CurrentGrade E$1.16-9.2% Hist 90D α
32
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PALI Turnaround Squeeze
While PALI currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.64) and Max Pain ($1.22) forces dealer call-delta covering toward $3.00.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PALI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PALI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PALI Stock dropped -2.52% Today — RQD Quant Desk Flash
Palisade Bio Inc. (PALI) dropped -2.52% to $1.16, trading at 3% of its 52-week range ($1.1 – $2.86). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($1.1 – $2.86) with RSI-14 at 30.1 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.16 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: PALI Exhibits 3.01x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live PALI Headlines & Catalysts
MARKET WIREInvesting.com • 18h ago
H.C. Wainwright reiterates Palisade Bio stock rating at buyInvesting.com report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 21h ago
Palisade Bio (Nasdaq:PALI) - Stock AnalysisSimply Wall St report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A gut inflammation marker fell 58.8% in five patients after 14 days on Palisade Bio’s experimental drug.Stock Titan report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Counsel receives 787,300 stock units at Palisade Bio (PALI), subject to service-based vesting.Stock Titan report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSimply Wall St • 1d ago
Palisade Bio's US$26m Market Cap Fall Books Insider LossesSimply Wall St report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
Palisade Bio (PALI) Holds Above $1.37 Support as Shares Edge Up 0.70% to $1.44 - Total Put Callhttps://www.dars.gov.et/ report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
PALISADE BIO, INC. Initial Statement of Beneficial OwnershipStock Titan report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeekingAlpha • 20h ago
Palisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 InhibitorPalisade Bio earns a Buy rating as PALI-2108 advances in ulcerative colitis. Click here to read my most recent analysis of PALI stock.
RISK WATCHYahoo • 5d ago
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative ColitisPALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability 29 of 30 planned U.S. sites
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PALI)
- ✓Walkthrough of PALI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PALI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -45.54%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.19H $1.19L $1.16C $1.16VOL 3.09M
RES: $2.20SUP: $1.07SMA50: $1.64SMA200: $1.85
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PALI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PALI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PALI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PALI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PALI)
Health Care Rank #718 of 1016
⚔️ ARTV vs PALI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PALI vs. ARTV, PLX, DTIL, IKT)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Palisade Bio Inc. (PALI) ranks #718 by composite RQD confidence (32/100, grade E) and #573 by equity capitalization ($202.2M). Within this direct 5-issuer industry benchmark cohort, PALI leads on earnings valuation at N/A trailing P/E, while PLX leads on capital efficiency and profitability with -13.0% ROIC and 48.8% gross margin. PALI currently leads its immediate peer cohort in composite quantitative strength at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PALI
ACTIVE
Palisade Bio Inc. | E | 32/100 | — | — | -35.0% | -2.52% | $202.2M | Benchmark Subject |
| ARTV Artiva Biotherapeutics Inc. | E | 27/100 | — | — | -35.0% | -0.95% | $204.8M | /artv-vs-pali → |
| PLX Protalix BioTherapeutics Inc. | E | 23/100 | — | 48.8% | -13.0% | -0.77% | $208.7M | /plx-vs-pali → |
| DTIL Precision BioSciences Inc. | E | 30/100 | — | — | -35.0% | -5.11% | $194.9M | /dtil-vs-pali → |
| IKT Inhibikase Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -7.19% | $216.3M | /ikt-vs-pali → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001357459In its most recent audited fiscal period (FY2025, filed 2025-12-31), Palisade Bio Inc. (PALI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$16.8M, operating cash flow of -$10.8M, and free cash flow of -$10.8M (+11.0% YoY). On the balance sheet, PALI closed FY2025 with $134.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$16.8M | -$10.8M | -$10.8M | $134.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$14.4M | -$12.2M | -$12.2M | $10.9M | — |
| FY2023 (FY) | 2023-12-31 | $250.0K | -$12.3M | -$11.1M | -$11.1M | — | — |
3. PALI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PALI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Palisade Bio Inc. (NASDAQ: PALI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.16 (-2.52% 1D, market cap $202.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
How does PALI compare to ARTV and PLX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PALI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARTV (Artiva Biotherapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $204.8M) and PLX (Protalix BioTherapeutics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -13.0%, cap $208.7M). Among the 5-stock peer group, PALI leads on earnings multiple (N/A) while PLX leads on capital efficiency (-13.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PALI?
Per PALI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001357459), Palisade Bio Inc. generated $0 in revenue, -$16.8M in net income, and -$10.8M in free cash flow against $134.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PALI trading relative to its 50-day, 200-day, and 52-week technical levels?
PALI last traded at $1.16 (-2.52% on volume of 3,090,613 shares), positioning the stock -29.27% below its 50-day simple moving average ($1.64) and -37.30% below its 200-day simple moving average ($1.85). Across its 52-week range of $1.10 to $2.86, PALI sits at the 3.4% percentile with a 14-day RSI of 30.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.02 to $1.30).
PALI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PALI stock moving today?
Why PALI Stock dropped -2.52% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 32/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
PALI — Palisade Bio Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:40:58Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, PALI scores 43 out of 100 with a letter grade of D- and a verdict of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 9/20 (ROIC of -35%; FCF yield of -5.23%); Whale 13F Flow at 9/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 12/20 (beta of 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z of 2.5; Piotroski F of 2/9; Debt/Equity of 0.5). For a prospective investor, the weakest pillars are insider conviction and the cash engine. The fundamental pillar reflects negative return on invested capital and negative free cash flow yield, meaning the company is not currently generating cash returns on the capital deployed. The forensic pillar is middling rather than distressed, with a Piotroski score of 2 out of 9 signaling weak fundamental quality. Upside drivers cited in the source data are limited to the news flow and institutional activity noted below; the rating itself frames the near-term setup as vulnerable. Valuation tradeoffs cannot be assessed on earnings because P/E and EPS are not available in source data. This analysis is educational and is not personalized financial advice.
Business
Palisade Bio Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company carries a market capitalization of $0.2B. The source data does not describe its specific products, customers, or revenue model. Reported revenue is $0.0M in FY 2025 and FY 2024 and $0.2M in FY 2023, per the SEC financials.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-18.1M | $-16.8M | N/A | $-10.8M | $133.4M | N/A |
| FY 2024 | $0.0M | $-14.9M | $-14.4M | N/A | $-12.2M | $9.8M | N/A |
| FY 2023 | $0.2M | $-13.1M | $-12.3M | N/A | $-11.1M | N/A | N/A |
Per the SEC financials, the company reported operating losses in each period shown, with margins of 0% across gross, operating, and net measures per the market data. ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, both as referenced in the Roarable RQD rating. Reported cash rose to $133.4M in FY 2025 from $9.8M in FY 2024, and debt is listed as N/A in the filings provided, with a Debt/Equity ratio of 0.5 per the RQD rating.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts feed, the flow is headline-driven and includes the following items:
- A report that a gut inflammation marker fell 58.8% in five patients after 14 days on the company's experimental drug (Stock Titan), flagged YELLOW.
- An H.C. Wainwright reiteration of a buy rating on the stock (Investing.com), flagged YELLOW.
- A grant of 787,300 stock units to Counsel, subject to service-based vesting (Stock Titan), flagged YELLOW.
- A Simply Wall St item titled as a US$26m market cap fall with insider losses, flagged RED under RISK WATCH.
- General market-wire coverage from Yahoo Finance Singapore and Simply Wall St, flagged YELLOW.
The RED risk-watch item concerns insider losses following the market cap decline. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.
Open Questions
- What products or pipeline assets does the company hold, and what stage are they at?
- What are the terms and timing of the cash position reported at $133.4M in FY 2025, given cash of $9.8M in FY 2024?
- What is the debt structure behind the Debt/Equity ratio of 0.5, given that debt is listed as N/A?
- What is the size and timing of the insider losses and stock-unit grants referenced in the news feed?
- What is the company's current cash runway relative to its negative free cash flow?
PALI Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Palisade Bio Inc. (PALI) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance Singapore • 15h ago
Palisade Bio, Inc. (PALI) stock price, news, quote and history Yahoo Finance Singapore report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 18h ago
H.C. Wainwright reiterates Palisade Bio stock rating at buy Investing.com report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 21h ago
Palisade Bio (Nasdaq:PALI) - Stock Analysis Simply Wall St report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A gut inflammation marker fell 58.8% in five patients after 14 days on Palisade Bio’s experimental drug. Stock Titan report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Counsel receives 787,300 stock units at Palisade Bio (PALI), subject to service-based vesting. Stock Titan report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Simply Wall St • 1d ago
Palisade Bio's US$26m Market Cap Fall Books Insider Losses Simply Wall St report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
Palisade Bio (PALI) Holds Above $1.37 Support as Shares Edge Up 0.70% to $1.44 - Total Put Call https://www.dars.gov.et/ report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
PALISADE BIO, INC. Initial Statement of Beneficial Ownership Stock Titan report covering Palisade Bio Inc. (PALI) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PALI Bull vs. Bear Conversation Board — What's Your Call at $1.16?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PALI 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.02 (-12.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is PALI (D- • RQD 43/100) a Buy at $1.16?
Welcome to the PALI (Palisade Bio Inc.) Roar Pit. Current RQD Composite is 43/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.93 (-19.8%)
Spot @ $1.16 Pump the brakes on PALI — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on PALI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Palisade Bio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.37 (+18.1%)
Spot @ $1.16 PALI cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on PALI, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.16 (52-wk range $1.10 - $2.86), any beat on forward guidance forces shorts and underweight funds to chase.